felin
infecti
periton
first
describ
highli
fatal
progress
immunopatholog
diseas
domest
wild
felida
holzworth
fip
occur
worldwid
current
one
lead
infecti
caus
death
cat
caus
agent
fip
felin
coronaviru
fcov
ubiquit
virtual
cat
popul
seroposit
depend
environ
geograph
area
seropost
cat
eventu
develop
fip
addi
jarrett
fcov
envelop
singlestrand
positivesens
rna
viru
belong
coronavirida
famili
within
order
nidoviral
gorbalenya
et
al
fcov
classifi
two
serotyp
ii
accord
amino
acid
sequenc
spike
protein
herrewegh
et
al
addit
serotyp
divid
two
distinctli
differ
pathotyp
base
pathogen
cat
common
pathotyp
field
felin
enter
coronaviru
fecv
caus
mild
often
unappar
enter
infect
sharp
contrast
infect
virul
pathotyp
design
felin
infecti
periton
fip
fatal
coronavirusinduc
system
diseas
domest
wild
felid
patholog
associ
fip
multifoc
granulomat
vascul
consid
elicit
exagger
activ
subsequ
extravas
leukocyt
chang
express
adhes
molecul
circul
leukocyt
preced
margin
emigr
reason
express
leukocyt
adhes
molecul
may
alter
fip
present
studi
express
princip
adhes
molecul
involv
leukocyt
transmigr
peripher
blood
leukocyt
cat
natur
occur
fip
n
control
n
quantifi
flow
cytometri
use
formaldehydebas
rapid
leukocyt
prepar
techniqu
tand
blymphocyt
fip
patient
exhibit
higher
express
subunit
compos
b
integrin
lymphocyt
functionassoci
antigen
lfa
addit
express
subunit
b
integrin
late
antigen
vla
elev
blymphocyt
fip
patient
express
combin
form
b
integrin
antigen
elev
monocyt
wherea
densiti
reduc
popul
fip
granulocyt
fip
cat
display
increas
express
chain
observ
suggest
leukocyt
fip
patient
show
sign
system
activ
caus
extravas
surround
tissu
ultim
contribut
pyogranuloma
format
seen
fip
elsevi
bv
right
reserv
felin
infecti
periton
viru
fipv
manifest
devast
highli
lethal
system
diseas
call
fip
pedersen
fip
character
fibrin
granulomat
seros
often
proteinrich
effus
bodi
caviti
pyo
granulomat
inflammatori
lesion
variou
organ
weiss
scott
b
heterogen
sometim
confus
histopatholog
pictur
fip
one
distinct
featur
stand
multifoc
granulomat
vascul
restrict
small
mediums
vein
morpholog
vascul
typifi
venou
periven
circular
cell
infiltr
domin
monocytesmacrophag
intermingl
neutrophil
lymphocyt
kipar
et
al
vascul
previous
regard
induc
type
iii
hypersensit
reaction
involv
deposit
immun
complex
within
venul
lead
complement
activ
jacobsegeel
et
al
pedersen
boyl
howev
kipar
cowork
demonstr
morpholog
cellular
composit
distribut
vascular
lesion
fip
differ
significantli
immunecomplexmedi
vascular
inflammatori
process
furthermor
demonstr
fcov
antigen
within
intravascular
leukocyt
among
cell
fip
granuloma
indic
phlebiti
initi
activ
fcovinfect
circul
monocyt
excess
number
activ
monocyt
emigr
blood
circul
accumul
periven
exagger
extravas
associ
enhanc
local
releas
matrix
metalloproteinas
b
mmp
lead
endotheli
barrier
dysfunct
kipar
et
al
consid
import
leukocyt
extravas
pathogenesi
fip
compar
studi
aim
investig
key
pathogen
event
crucial
step
process
leukocyt
recruit
parenchyma
adher
circul
leukocyt
vascular
endotheli
cell
ec
facilit
adhes
molecul
express
surfac
particip
cell
base
biochem
properti
molecular
structur
adhes
molecul
group
three
gene
famili
selectin
integrin
immunoglobulin
ig
supergen
famili
carlo
harlan
initi
adhes
interact
involv
particip
endotheli
selectin
bind
sialyl
lewi
x
slex
carbohydr
moieti
found
termin
domain
glycoprotein
express
leukocyt
surfac
rel
low
affin
natur
bind
result
hydrodynam
shear
flow
leukocyt
roll
along
vessel
wall
transient
bound
leukocyt
subsequ
activ
encount
immobil
chemokin
endotheli
surfac
activ
step
enabl
strengthen
adhes
forc
leukocyt
becom
firmli
attach
endothelium
firm
adhes
achiev
interplay
integrin
ig
supergen
famili
receptor
ebnet
vestweb
integrin
heterodim
glycoprotein
consist
two
noncoval
associ
dissimilar
protein
design
b
chain
integrin
divid
differ
group
depend
common
b
chain
b
subunit
combin
l
subunit
build
lymphocyt
functionassoci
antigen
lfa
form
antigen
respons
interact
intercellular
adhes
molecul
icam
present
constitut
ec
markedli
induc
inflamm
b
integrin
name
late
antigen
vla
share
common
b
chain
link
number
chain
receptor
contain
subunit
one
b
integrin
respons
leukocyt
extravas
due
interact
vascular
cell
adhes
molecul
vcam
present
activ
endothelium
belong
ig
supergen
famili
built
sever
immunoglobulin
domain
barreiro
sanchezmadrid
carlo
harlan
given
larg
number
leukocyt
fip
lesion
hypothes
fipv
infect
could
alter
express
adhes
molecul
leukocyt
might
favor
leukocyteendotheli
adher
subsequ
migrat
therebi
induc
endotheli
cell
damag
contribut
pathogenesi
fip
despit
critic
role
patholog
outcom
express
adhes
molecul
peripher
leukocyt
fipv
infect
remain
mainli
undescrib
identif
adhes
molecul
alter
express
fip
provid
invalu
insight
elucid
pathogenesi
essenti
data
also
assist
develop
accur
diagnost
method
therefor
princip
aim
present
studi
quantifi
express
adhes
molecul
main
peripher
leukocyt
popul
fip
patient
healthi
control
flow
cytometri
use
formaldehydebas
rapid
leukocyt
prepar
techniqu
hamblin
et
al
panel
thoroughli
valid
monoclon
antibodi
main
adhes
molecul
associ
leukocyt
transendotheli
migrat
studi
fifteen
cat
natur
infect
fcov
clinic
strongli
suspect
fip
base
cat
profil
clinic
sign
blood
andor
exud
examin
includ
studi
characterist
patholog
find
cat
list
tabl
case
presumpt
diagnosi
fip
confirm
postmortem
examin
compris
necroscopi
histolog
immunohistochemistri
fcovantigen
patient
receiv
corticosteroid
immunosuppress
therapi
serolog
felin
immunodefici
viru
fiv
felin
leukaemia
viru
felv
perform
use
commerci
avail
elisa
kit
wit
felvfiv
synbiot
corpor
san
diego
ca
usa
accord
procedur
advis
manufactur
cat
confirm
infect
fiv
felv
control
group
twelv
specif
pathogen
free
spf
cat
perman
kept
anim
facil
faculti
veterinari
medicin
ghent
univers
time
sampl
cat
clinic
healthi
show
hematolog
biochem
abnorm
attribut
fip
infecti
diseas
clientown
fip
cat
use
basi
avail
spf
cat
current
present
anim
facil
enclos
control
possibl
match
control
onetoon
case
base
age
factor
studi
methodolog
approv
ethic
committe
faculti
veterinari
medicin
ghent
univers
applic
inform
consent
obtain
owner
patient
peripher
blood
leukocyt
patient
control
prepar
label
flow
cytometri
formaldehydebas
rapid
leukocyt
prepar
techniqu
peripher
blood
sampl
extern
jugular
vein
heparin
leo
zaventem
belgium
final
concentr
uml
fresh
blood
mix
within
min
equal
volum
prewarm
paraformaldehyd
pf
phosphat
buffer
salin
pb
vel
chemic
ucb
brussel
belgium
incub
min
excess
ml
warm
lyse
buffer
ph
ammonium
chlorid
tri
ad
incub
erythrocyt
lyse
min
cell
sediment
centrifug
g
min
room
temperatur
supernat
discard
leukocyterich
pellet
wash
twice
pb
final
leukocyt
resuspend
ml
pb
store
label
next
day
prevent
nonspecif
bind
leukocyt
first
preincub
pb
contain
bovin
serum
albumin
bsa
sigmaaldrich
gmbh
steinheim
germani
normal
goat
serum
ng
min
thereaft
cell
wash
pb
incub
satur
amount
monoclon
antibodi
mab
differ
adhes
molecul
separ
tube
h
wash
step
alexa
fluor
goat
antimous
igg
igm
ab
molecular
probe
eugen
oregon
usa
ad
incub
carri
h
next
residu
free
bind
site
secondari
ab
satur
ad
excess
nonspecif
subclass
match
ab
rais
speci
primari
ab
adhes
molecul
mous
igg
igm
min
second
stage
stain
procedur
sampl
divid
three
addit
tube
defin
differ
leukocyt
subset
within
adhes
molecul
tcell
identifi
mab
nishimura
et
al
visual
fluorescein
isothiocyan
fitc
conjug
goat
antimous
igg
ab
molecular
probe
mab
prelabel
alexa
fluor
fab
fragment
zenon
mous
igg
label
kit
invitrogen
carlsbad
usa
use
marker
bcell
doubl
stain
antigranulocyt
vmrd
inc
pullman
wa
usa
preconjug
zenon
alexa
fluor
rphycoerythrin
pe
mous
igg
label
kit
invitrogen
respect
perform
distinguish
monocyt
posit
granulocyt
doubl
posit
control
sampl
antibodi
prepar
subclass
match
irrelev
mab
run
parallel
identifi
nonspecif
background
fluoresc
mab
human
dog
target
speci
either
react
cat
accord
manufactur
previous
shown
crossreact
felin
leukocyt
kanam
et
al
mab
rais
human
antigen
unknown
felin
crossreact
tissu
distribut
fluoresc
pattern
antigen
recogn
mab
determin
cat
almost
ident
human
indic
mab
recogn
cat
homologu
human
antigen
optim
dilut
ab
determin
prior
experi
batch
ab
use
throughout
studi
detail
antibodi
see
tabl
label
leukocyt
resuspend
ml
pf
pb
left
overnight
dark
flow
cytometr
analysi
flow
cytometri
perform
use
facscanto
flow
cytomet
equip
facsdiva
softwar
bd
bioscienc
mountain
view
ca
usa
instrument
calibr
experi
lot
fluoresc
refer
bead
rainbow
calibr
particl
peak
bd
bioscienc
ensur
rel
fluoresc
valu
compar
run
sampl
minimum
event
acquir
within
leukocyt
gate
forward
side
scatter
fsc
ssc
collect
linear
scale
fluoresc
measur
use
five
decad
logarithm
scale
gate
set
isol
singlet
event
debri
aggreg
next
leukocyt
subpopul
care
delin
accord
light
scatter
characterist
cell
marker
express
fig
mean
fluoresc
intens
mfi
arbitrari
unit
linear
convers
log
fluoresc
use
rel
indic
surfac
densiti
adhes
molecul
respect
leukocyt
popul
valu
correct
subtract
control
fluoresc
subpopul
primari
mab
substitut
irrelev
isotyp
match
mab
unimod
distribut
marker
result
express
mfi
whole
leukocyt
subpopul
bimod
distribut
marker
result
describ
two
way
proport
brightli
posit
cell
within
subpopul
next
mfi
brightli
subset
spectral
overlap
alexa
fluor
pelabel
antibodi
correct
use
electron
compens
examin
whether
differ
express
attribut
differ
cell
size
fsc
measur
differ
cell
popul
patient
compar
control
result
summar
analyz
use
nonparametr
method
sinc
distribut
data
nongaussian
receptor
densiti
express
mfi
present
median
valu
percentil
rang
signific
differ
fip
patient
control
calcul
mannwhitney
utest
twotail
correl
calcul
use
spearman
rank
test
p
valu
equal
lower
consid
statist
signific
statist
analys
perform
use
spss
spss
inc
chicago
il
usa
peripher
blood
leukocyt
patient
control
prepar
antibodi
label
flow
cytometri
formaldehydebas
leukocyt
prepar
techniqu
repres
light
scattergram
peripher
blood
leukocyt
healthi
subject
fip
cat
obtain
techniqu
shown
fig
strike
differ
fscssc
profil
leukocyt
healthi
fip
cat
note
techniqu
appli
blood
healthi
subject
permit
clearli
defin
lymphocyt
monocyt
granulocyt
base
intrins
forward
sideward
light
scatter
characterist
contrast
main
leukocyt
popul
could
identifi
simpli
fsc
ssc
properti
fip
sampl
consider
overlap
granulocyt
monocyt
furthermor
substanti
diminut
lymphocyt
count
fip
cat
made
difficult
separ
popul
cell
debri
sinc
gate
leukocyt
popul
base
physic
characterist
could
appli
fip
sampl
discrimin
band
tlymphocyt
within
lymphocyt
gate
specif
cell
marker
use
identifi
differ
subpopul
leukocyt
control
patient
one
color
stain
tlymphocyt
blymphocyt
plot
ssc
two
color
dot
plot
antigranulocyt
monocyt
granulocyt
shown
fig
final
ascertain
leukocyt
prepar
techniqu
render
surfac
antigen
intracellular
antigen
access
antibodi
process
permeabilis
leukocyt
membran
evidenc
failur
stain
cell
antibodi
cytoplasm
antigen
vimentin
data
shown
follow
distribut
pattern
adhes
molecul
observ
healthi
cat
well
fip
cat
histogram
analysi
within
leukocyt
subpopul
bcell
adhes
molecul
show
unimod
fluoresc
distribut
indic
adhes
molecul
express
none
blymphocyt
tlymphocyt
distribut
adhes
molecul
seen
blymphocyt
except
express
tlymphocyt
character
clear
bimod
distribut
contain
neg
posit
subset
express
profil
adhes
molecul
granulocyt
monocyt
similar
entir
granulocyt
monocyt
popul
brightli
posit
dimli
posit
present
unimod
distribut
fluoresc
intens
contrast
histogram
popul
show
bimod
distribut
express
monocyt
granulocyt
reveal
unimod
peak
howev
monocyt
express
moder
high
level
molecul
wherea
granulocyt
express
littl
surfac
repres
histogram
adhes
molecul
unimod
bimod
express
pattern
shown
fig
surfac
express
adhes
molecul
compar
fip
cat
n
healthi
control
n
use
logarithm
mfi
paramet
entir
leukocyt
subpopul
unimod
distribut
molecul
brightli
posit
subset
bimod
distribut
molecul
addit
proport
brightli
posit
cell
within
subpopul
compar
patient
control
adhes
molecul
bimod
distribut
signific
differ
observ
level
slex
express
leukocyt
popul
patient
compar
control
fig
howev
high
degre
intersubject
variabl
express
slex
leukocyt
popul
fipvinfect
uninfect
group
noteworthi
proport
monocyt
granulocyt
popul
brightli
express
slex
also
vari
greatli
among
individu
signific
differ
percentag
cell
express
molecul
patient
control
compar
granulocyt
express
low
level
b
integrin
level
significantli
differ
patient
control
contrari
lymphocyt
monocyt
display
moder
high
express
level
signific
differ
mfi
associ
blymphocyt
monocyt
detect
fip
cat
compar
control
cat
rel
number
tlymphocyt
appear
compar
fip
cat
ae
healthi
control
ae
express
b
integrin
increas
leukocyt
fip
patient
specif
l
chain
express
fip
lymphocyt
band
tcell
significantli
higher
control
granulocyt
monocyt
fip
patient
express
significantli
higher
densiti
chain
molecul
express
common
b
chain
regul
leukocyt
popul
patient
group
although
differ
achiev
signific
granulocyt
popul
possibl
observ
differ
fluoresc
due
differ
size
cell
patient
control
group
explor
compar
mean
forward
scatter
substanti
differ
mean
forward
scatter
blymphocyt
tlymphocyt
granulocyt
monocyt
show
differ
mfi
attribut
differ
size
group
mfi
valu
express
significantli
differ
patient
control
leukocyt
popul
fig
express
found
extrem
variabl
monocyt
granulocyt
fip
cat
correl
adhes
molecul
express
differ
leukocyt
popul
aspect
diseas
sought
use
spearman
rank
coeffici
immun
diseas
statu
patient
defin
variou
laboratori
data
lymphocyt
count
neutrophil
count
rel
absolut
number
blood
albumin
signific
correl
found
express
blymphocyt
albumin
level
spearmann
coeffici
p
fip
patholog
typic
character
widespread
granulomat
vascular
lesion
accept
today
inflammatori
reaction
fip
lesion
initi
excess
leukocyt
migrat
bloodstream
surround
tissu
kipar
et
al
date
adhes
molecul
play
major
role
leukocyt
extravas
well
character
fipv
infect
best
knowledg
first
compar
analysi
quantit
express
leukocyt
adhes
molecul
normal
fip
cat
use
whole
blood
flow
cytometr
assay
current
research
well
awar
express
functionassoci
antigen
like
adhes
molecul
rapidli
artefactu
modul
cell
activ
vitro
activ
readili
occur
convent
cell
prepar
label
procedur
forsyth
levinski
macey
et
al
overcom
problem
minim
ex
vivo
alter
success
appli
formaldehydebas
rapid
leukocyt
prepar
techniqu
previous
design
prepar
human
leukocyt
purpos
hamblin
et
al
addit
well
known
excess
formaldehyd
fixat
caus
permeat
cell
membran
macey
mccathi
would
implic
adhes
molecul
express
membran
surfac
also
intracellular
storag
pool
adhes
molecul
becom
access
antibodi
therefor
first
ascertain
techniqu
conserv
plasma
membran
integr
evidenc
lack
cell
stain
antibodi
cytoplasm
antigen
vimentin
taken
togeth
except
possibl
chang
due
process
venipunctur
believ
find
repres
true
state
adhes
molecul
surfac
leukocyt
circul
pool
patient
includ
studi
select
great
care
attempt
avoid
potenti
confound
factor
sinc
glucocorticoid
report
affect
product
variou
cytokin
turn
affect
express
adhes
molecul
verifi
fip
cat
receiv
glucocorticoid
immunosuppress
therapi
torsteinsdottir
et
al
addit
exact
influenc
pathogen
adhes
molecul
express
unknown
confirm
fip
patient
affect
intercurr
infect
felv
fiv
adhes
molecul
coordin
variou
phase
leukocyt
adher
endothelium
stepwis
fashion
regul
mechan
ligand
bind
present
studi
aim
assess
express
princip
adhes
molecul
involv
leukocyteendothelium
interact
demonstr
major
adhes
molecul
display
unimod
fluoresc
distribut
therefor
chang
express
level
mfi
rather
distribut
posit
cell
appear
appropri
tool
determin
whether
alter
express
associ
fipv
infect
first
step
extravas
characterist
leukocyt
roll
phenomenon
mediat
endotheli
selectin
recogn
slex
carbohydr
moieti
termin
domain
glycoprotein
leukocyt
surfac
result
show
consider
intersubject
variat
express
slex
leukocyt
popul
wide
biolog
rang
slex
express
level
seen
patient
group
also
control
group
consid
rel
homogen
group
young
adult
spf
cat
find
consist
studi
rebuck
finn
demonstr
inher
variabl
express
adhes
molecul
especi
lselectin
granulocyt
within
healthi
human
rebuck
finn
second
step
adher
cascad
involv
firm
attach
leukocyt
endothelium
larg
mediat
interact
integrin
member
ig
supergen
famili
b
integrin
promot
tight
adher
leukocyt
endotheli
ligand
found
leukocyt
wherea
present
myeloid
cell
studi
demonstr
granulocyt
monocyt
fip
cat
display
significantli
circul
lymphocyt
express
higher
densiti
control
subject
increas
integrin
express
regul
least
two
mechan
occur
rapidli
within
minut
gradual
time
cours
h
rapid
alter
achiev
mobil
intracellular
storag
pool
cell
surfac
circul
granulocyt
monocyt
lymphocyt
signific
amount
store
intracellular
vesicl
upon
cell
activ
transloc
within
minut
membran
surfac
mazzon
ricevuti
undoubtedli
allow
rapid
prompt
respons
cell
develop
inflammatori
process
might
explain
predomin
inflammatori
infiltr
fip
takano
et
al
addit
rapid
chang
cellsurfac
express
quantit
alter
integrin
receptor
occur
longer
stimul
hour
day
involv
de
novo
integrin
subunit
synthesi
lymphocyt
adhes
reli
greatli
sinc
littl
store
intracellularli
regul
adhes
molecul
depend
second
mechan
substanti
slower
process
mazzon
ricevuti
factor
may
underlin
rel
slow
lymphocyt
respons
activ
turn
may
reflect
later
accumul
develop
fip
lesion
kipar
et
al
consist
origin
name
late
antigen
leukocyt
b
integrin
increas
express
gradual
sever
day
activ
uniqu
among
b
integrin
abil
bind
addit
matrix
protein
endotheli
ligand
latter
member
ig
supergen
famili
resid
cytokineactiv
endothelium
carlo
harlan
result
show
felin
neutrophil
like
human
counterpart
express
rel
low
level
confirm
prevail
view
play
rel
minor
role
neutrophil
adhes
contrast
monocyt
lymphocyt
express
moder
high
level
interact
propos
altern
emigr
pathway
cell
studi
increas
express
subunit
blymphocyt
fip
patient
demonstr
consist
immunohistochem
find
kipar
et
al
berg
et
al
examin
cellular
composit
fip
lesion
show
lesion
without
extend
necrosi
bcell
plasmacel
progress
infiltr
granuloma
henc
replac
macrophag
form
broad
outer
rim
berg
et
al
kipar
et
al
sinc
critic
involv
monocyt
interact
endothelium
interest
despit
cell
type
predomin
fip
granuloma
express
level
significantli
lower
monocyt
fip
patient
compar
healthi
control
meerschaert
furi
show
monocyt
adhes
human
ec
monolay
inhibit
complet
ec
preincub
combin
mab
b
integrin
meerschaert
furi
vitro
observ
suggest
repres
altern
pathway
transendotheli
migrat
monocyt
given
avail
least
one
pathway
suffici
support
normal
level
migrat
togeth
find
make
us
assum
monocyt
extravas
fip
larg
depend
b
interact
member
ig
supergen
famili
member
express
endotheli
cell
also
lymphocyt
monocyt
macrophag
well
known
homotyp
heterotyp
lymphocyt
adhes
mediat
interact
facilit
lymphocyt
function
includ
antigen
recognit
lymphocyt
costimul
cytotox
addit
shown
play
essenti
role
monocytelymphocyt
commun
hubbard
rothlein
sinc
central
role
immun
respons
explor
express
molecul
fip
differ
note
express
lymphocyt
monocyt
patient
healthi
control
date
publish
data
express
granulocyt
limit
recent
report
human
neutrophil
express
regul
vitro
stimul
endotoxin
tumor
necrosi
factor
tnf
specul
regul
may
allow
neutrophil
assist
reach
final
destin
increas
sticki
via
interact
wang
et
al
flow
cytometr
analys
monoclon
antibodi
demonstr
felin
granulocyt
express
moder
amount
express
granulocyt
fip
group
character
high
variabl
patient
might
respons
lack
signific
differ
control
group
variabl
might
correl
stage
diseas
howev
hypothesi
could
thoroughli
assess
sinc
spontan
occur
fip
possibl
determin
moment
infect
exhaust
followup
cat
euthanat
blood
sampl
higher
express
adhes
molecul
patient
consist
gener
activ
peripher
leukocyt
howev
studi
determin
mechan
underli
alter
express
sinc
small
proport
circul
monocyt
infect
fipv
togeth
find
granulocyt
lymphocyt
suscept
fipv
infect
show
similar
express
chang
monocyt
indic
direct
effect
viral
infect
account
observ
alter
seem
like
indirect
effect
complex
chang
cytokin
milieu
associ
advanc
fip
diseas
caus
alter
cell
surfac
molecul
densiti
varieti
cytokin
shown
influenc
adhes
molecul
express
mainli
tumor
necrosi
factor
tnfa
interleukin
il
interferon
ifn
g
implic
regul
integrin
studi
cat
fip
shown
cytokin
express
markedli
alter
compar
healthi
anim
specif
note
express
proinflammatori
cytokin
tnfa
significantli
increas
fip
like
account
activ
leukocyt
circul
goitsuka
et
al
kiss
et
al
takano
et
al
addit
altern
explan
find
may
differ
rel
immatur
leukocyt
fip
cat
rate
migrat
cell
bone
marrow
blood
tissu
like
faster
fip
patient
normal
cat
result
accumul
less
matur
cell
circul
fip
hematolog
often
character
neutrophilia
accompani
increas
count
left
shift
less
matur
band
neutrophil
provid
evid
increas
recruit
bone
marrow
differ
integrin
express
known
occur
leukocyt
differenti
alter
surfac
level
may
therefor
reflect
differ
matur
level
cell
patient
compar
control
elghetani
kansa
et
al
chang
composit
fip
peripher
lymphocyt
may
also
underli
increas
level
express
seen
cell
shown
tlymphocyt
undergo
phenotyp
chang
upon
encount
specif
antigen
convers
memori
type
involv
increas
level
express
adhes
molecul
sander
et
al
whether
observ
chang
cell
adhes
molecul
express
function
consequ
contribut
diseas
process
specul
whilst
quantit
chang
express
associ
increas
adhes
vitro
recogn
adhes
vivo
also
occur
without
increas
level
surfac
express
fact
bodi
data
confirm
regul
integrinmedi
adher
seem
complex
pure
quantit
chang
express
molecul
cell
surfac
appear
steadyst
condit
integrin
molecul
cell
surfac
rel
low
function
activ
state
upon
activ
leukocyt
molecul
convert
activ
state
result
higher
affin
respect
ligand
qualit
chang
believ
least
equal
import
quantit
chang
vivo
activ
mani
adhes
molecul
arnaout
examin
level
surfac
express
adhes
molecul
affin
state
molecul
determin
howev
sinc
key
role
leukocyt
adher
increas
number
adhes
molecul
express
cell
surfac
may
predispos
leukocyt
increas
adhes
adher
gener
accept
ratelimit
step
transmigr
occur
rel
high
adher
follow
rel
high
transmigr
adher
diapedes
leukocyt
may
releas
proteas
toxic
oxygen
metabolit
vasoact
substanc
togeth
lead
endotheli
injuri
subsequ
loss
vascular
integr
edema
tissu
injuri
contribut
hallmark
lesion
fip
recruit
characterist
leukocyt
infiltr
fip
regul
express
leukocyt
adhes
molecul
conjunct
reciproc
express
counter
receptor
vascular
endothelium
given
site
diseas
specif
believ
relat
endotheli
express
combin
vascular
adhes
molecul
would
great
valu
assess
express
distribut
cytokineinduc
endotheli
ligand
site
fip
lesion
futur
summari
demonstr
leukocyt
fip
cat
show
sign
activ
peripher
circul
concern
adhes
like
prime
blood
leukocyt
fip
one
mechan
behind
excess
recruit
accumul
immun
cell
result
granuloma
format
ultim
contribut
indisput
pathogenesi
fip
diseas
find
may
provid
reliabl
laboratori
marker
support
ant
mortem
diagnosi
fip
present
still
challeng
howev
larger
studi
includ
patholog
condit
warrant
evalu
discrimin
power
paramet
fip
addit
detail
understand
leukocyt
interact
vascular
endotheli
cell
fip
offer
invalu
insight
could
promot
emerg
novel
therapeut
tool
interfer
leukocyt
recruit
subsequ
limit
tissu
injuri
